OPIOID USE DISORDER MARKET ANALYSIS

Global opioid use disorder market is estimated to be valued at US$ 3.24 Bn  in 2023, and is expected to exhibit a CAGR of 8.7% during the forecast period (2023-2030).

Analysts’ Views on Global Opioid Use Disorder Market:

Increasing investment & funding by government to combat the overdose epidemic of opioids is expected to drive growth of global opioid use disorder market  over the forecast period. For instance, on September 23, 2022, the U.S. Department of Health and Human Services’ (HHS) Overdose Prevention Strategy, the Health Resources and Services Administration (HRSA), announced investment of over US$ 104 Mn  to help clinicians who can prescribe  the opioid treatment buprenorphine. Moreover, on August 21, 2022, the U.S. Department of Health and Human Services (HHS) through the Substance Abuse and Mental Health Services Administration (SAMHSA), announced the award of US$ 79.1 Mn  in overdose prevention grants, as part of President Biden’s National Drug Control Strategy, the HHS Overdose Prevention Strategy, and the Biden-Harris Unity Agenda to address the opioid and overdose epidemic.

Figure 1. Global Opioid Use Disorder Market Share (%), By Drug Type, 2023

To learn more about this report, Request sample copy

Global Opioid Use Disorder Market– Drivers

Rising prevalence of opioid use disorder

Rising prevalence of opioid use disorder among the population is expected to drive growth of the the global opioid use disorder market over the forecast period. For instance, in 2020, according to the data published by National Institute on Drug Abuse, an estimated 2.7 Mn  people aged 12 or older, in the U.S. had an opioid use disorder (OUD) including 2.3 Mn  people with a prescription opioid use disorder.

 Increasing organic growth strategies such as product approval

Increasing organic growth strategies such as product approval by regulatory authorities to expand product portfolio of the key market players is expected to drive growth of the global opioid use disorder market over the forecast period. For instance, in April 2020, Amneal Pharmaceuticals, Inc., a pharmaceutical company, announced that it had received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of butrans (buprenorphine) transdermal system, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr. Amneal Pharmaceuticals, Inc. was granted the competitive generic Ttherapy (CGT) designation and 180 days of exclusivity for the 7.5 mcg/hr dose.

Figure 2. Global Opioid Use Disorder Market Share(%), By Region, 2023

To learn more about this report, Request sample copy

Global Opioid Use Disorder Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global opioid use disorder market over the forecast period. North America is estimated to hold 33.5 % of the market share in 2023. The market is expected to witness significant growth in the near future, owing to increasing organic growth strategies such as product approval by regulatory authorities to expand product portfolio of the key market players. For instance, in December 2021, Camurus AB, a pharmaceutical company, announced that its U.S. licensee Braeburn had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its updated New Drug Application (NDA) for Brixadi (buprenorphine) extended-release injections for the treatment of opioid use disorder. The CRL is a result of continued quality related deficiencies at Braeburn’s U.S. based third party manufacturer, identified by the FDA during a pre-approval inspection.

Global Opioid Use Disorder Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease had spread to over 100 countries across the globe, and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of drugs  from one place to another.

However, the COVID-19 had negative impact on the global opioid use disorder market, as patients with opioid use had limited access to opioid treatment programs during the COVID-19 public health emergency, whereas access to buprenorphine, an opioid drug treatment, remained undisrupted. For instance, on March 11, 2022, According to a report published by JAMA Health Forum, an international peer-reviewed journal (American Medical Association), patients with opioid use disorder (OUD) are less likely to receive opioid treatment due to disruptions in care during the COVID-19 pandemic. Access to the program has decreased. Opioid-related overdoses during the COVID-19 pandemic in the U.S. have decreased by 14% from 0.34 per 100,000 patients before the pandemic to 0.29 per 100,000 patients at the start of the pandemic. The recorded death rate is 69,710. 2020 is the 19th time a pandemic has occurred.

Global Opioid Use Disorder Market- Segmentation

Global opioid use disorder market  is segmented into drug type,  route of administration,  distribution channel, and  region.

• By drug type, the market is segmented into buprenorphine, methadone, naltrexone, and others. Out of which, buprenorphine segment is expected to hold a dominant position in the global opioid use disorder market during the forecast period due to increasing inorganic growth strategies such as partnership.
• By route of administration, the market is segmented into oral and parenteral. Out of which, parenteral segment is expected to hold a dominant position in the global opioid use disorder market during the forecast period due to increasing use of parenteral drug for the treatment of opioid disorders.
• By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, hospital pharmacies segment is expected to dominate the market over the forecast period due to increasing use of catheters in hospitals
• By region, the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Out of which, North America is expected to dominate the market over the forecast period due to increasing organic growth strategies such as product launches and approvals.

Among all the segmentation, the drug type segment is expected to dominate the market over the forecast period due to increasing organic growth strategies such as product launch by key market players to expand their product portfolio. For instance, in May 2020, Hikma Pharmaceuticals PLC., the multinational generic pharmaceutical company, launched buprenorphine hydrochloride injection, 0.3mg/mL, the generic version of buprenex [1] in the U.S. through its U.S. affiliate, Hikma Pharmaceuticals U.S.A.Inc.

Global Opioid Use Disorder Market- Cross Sectional Analysis

In Drug type segment buprenorphine is dominant in Europe region due to increasing organic growth strategies such as product approvals by regulatory authorties to expand key market’s players product portfolio. For instance, in November 2021, Camrus AB, a biotechnology company, announced that the European Medicines Agency (EMA) had accepted the company’s submission of a Type II variation application for Buvidal (buprenorphine) prolonged release injection to include the treatment of 2021%2D2028).">chronic pain.

Global Opioid Use Disorder Market: Key Developments

• On August 30, 2023, Emergent BioSolutions Inc., a company that provides  solutions for complex and urgent public health threats, announced that NARCAN Naloxone HCl Nasal Spray 4 mg will be available on shelves nationwide and online, in September 2023. Over-the-counter (OTC) access to NARCAN Nasal Spray offers more people the ability to respond in an opioid emergency, helping to save lives and keep people and communities safe.
• On March 29, 2023, Emergent BioSolutions Inc., a company that provides  solutions for complex and urgent public health threats, announced that the U.S. Food and Drug Administration (FDA) had approved NARCAN Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose. This decided at a time when approximately every eight minutes, a person dies from an opioid overdose and research shows the epidemic is escalating in the U.S. with increasing synthetic opioids.
• On March 23, 2023, Harm Reduction Therapeutics, a not-for-profit pharmaceutical company, announced that it has entered into a commercial supply agreement with Catalent, Inc., a leader in developing and delivering better treatments to patients around the world. Under this agreement, Catalent, Inc. will manufacture RiVive (3.0 mg), a naloxone nasal spray for harm reduction therapy for emergency treatment of known or suspected opioid overdose.
• In December 2022, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, announced the settlement agreement with State of New Hampshire, a department of Justice U.S. Under the term of agreement, Teva Pharmaceutical Industries Ltd., provides US$ 33.3 Mn  to the state of New Hampshire to address the opioid crisis.
• In June 2021, Alkem Laboratories Ltd., a pharmaceutical company, announced that U.S. Food and Drug Administration (U.S. FDA) had approved buprenorphine hydrochloride and naloxone hydrochloride sublingual tablets, the generic version of suboxone, used to treat opioid addiction.

Global Opioid Use Disorder Market: Trends

• Increasing inorganic growth strategies such as acquisition: Increasing inorganic growth strategies such as acquisition by key market players to streghten their market presence is expected to drive the global opiod use disorder market growth over the forecast period. For instance, in April 2021, Amneal Pharmaceuticals, Inc., a pharmaceutical company, and Kashiv BioSciences LLC., a pharmaceutical company, announced that Amneal Pharmaceuticals LLC., a pharmaceutical company, had completed its previously announced acquisition of Kashiv Specialty Pharmaceuticals, LLC., a wholly-owned subsidiary of Kashiv that focuses on the development of complex generics, innovative drug delivery platforms, and novel 505(b)(2) drugs.

Global Opioid Use Disorder Market: Restraint

• Product recall: Factors such as product recall and side effects associated with the use of opioids is expected to hamper the growth of the global opioid use disorder market over the forecast period. For instance, on July 14, 2021, according to U.S. Food and Drug Administration (FDA) Enforcement Report, Alvogen, a pharmaceuticals company, recalled  a single lot of buprenorphine and naloxone sublingual films due to subpotency. The recall affects buprenorphine and naloxone sublingual film 2 mg/0.5 mg, 30 pouches containing one sublingual film each (NDC 47781-355-11), from lot 36924 (Exp. 6/21).
• Counterbalance: The key market players are focusing s on maintaining quality of products to reduced product recall.

Global Opioid Use Disorder Market- Key Players

Major players operating in the global opioid use disorder market include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Hikma Pharmaceuticals PLC, Camurus AB, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Purdue Pharma LP, Alvogen, Faran Shimi Pharmaceutical, Novartis AG, Emplicure AB, MODASA Pharmaceuticals Pvt. Ltd.

Global Opioid Use Disorder Market : Definition: Opioid use disorder is a serious health issue that is rising globally in recent years. There are various medication-assisted treatment (MAT) options available to help patients who are suffering from this disorder. The main products used for the treatment are methadone, buprenorphine, and naltrexone. A deadly consequence of the opioid crisis is increased incidence of blood-borne infections, including hepatitis B virus and hepatitis C, human immunodeficiency virus (HIV), and bacteria that cause heart infections (endocarditis ).